Elena Giudice
About
Elena Giudice is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology.
According to data from OpenAlex, Elena Giudice has authored 33 papers receiving a total of 240 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Reproductive Medicine, 22 papers in Oncology and 8 papers in Obstetrics and Gynecology. Recurrent topics in Elena Giudice's work include Ovarian cancer diagnosis and treatment (23 papers), PARP inhibition in cancer therapy (15 papers) and Endometrial and Cervical Cancer Treatments (8 papers). Elena Giudice is often cited by papers focused on Ovarian cancer diagnosis and treatment (23 papers), PARP inhibition in cancer therapy (15 papers) and Endometrial and Cervical Cancer Treatments (8 papers). Elena Giudice collaborates with scholars based in Italy, United States and Germany. Elena Giudice's co-authors include Domenica Lorusso, Giovanni Scambia, Vanda Salutari, Caterina Ricci, Lucia Musacchio, Viola Ghizzoni, Floriana Camarda, Camilla Nero, Maria Teresa Perri and Cláudia Marchetti and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Annals of Oncology.
In The Last Decade
Elena Giudice
26 papers receiving 235 citations
Peers
Elena Giudice
Lorena Fariñas-Madrid Spain
Daliah Tsoref Israel
Beata Maćkowiak-Matejczyk Poland
Irina Tsibulak Austria
Justin Harold United States
Imre Pete Hungary
Koji Nishino Japan
Tong Shu China
И. В. Берлев Russia
A.M. Newtson United States
Citations per year, relative to Elena Giudice Elena Giudice (= 1×)
peers
Lorena Fariñas-Madrid
Countries citing papers authored by Elena Giudice
Since
Specialization
Citations
This map shows the geographic impact of Elena Giudice's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Giudice with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Giudice more than expected).
Fields of papers citing papers by Elena Giudice
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Elena Giudice. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Giudice. The network helps show where Elena Giudice may publish in the future.
Co-authorship network of co-authors of Elena Giudice
This figure shows the co-authorship network connecting the top 25 collaborators of Elena Giudice. A scholar is included among the top collaborators of Elena Giudice based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Giudice. Elena Giudice is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Leo, Michael C., et al.. (2026). Reframing Obesity in Knee Osteoarthritis: A Call for a Transdisciplinary Approach Beyond Biomechanics. Arthroscopy The Journal of Arthroscopic and Related Surgery. 42(1). 14–15.
2.
Signorelli, Mauro, Eliana Rulli, Giampaolo Di Martino, et al.. (2025). Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III–IV epithelial ovarian cancer: A systematic review and meta-analysis. European Journal of Cancer. 232. 116116–116116.
3.
Iannantuono, Giovanni Maria, Charalampos S. Floudas, Marco Filetti, et al.. (2025). Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023). European Journal of Cancer. 225. 115589–115589.
4.
Spinazzola, A, Giovanni Maria Iannantuono, Elena Giudice, et al.. (2025). Current landscape of T-cell engagers in early-phase clinical development in solid cancers. Frontiers in Immunology. 16. 1665838–1665838.
5.
Giudice, Elena, Tzu‐Ting Huang, Jayakumar R. Nair, et al.. (2024). The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. Nature Communications. 15(1). 2805–2805.
6.
Fagotti, Anna, Chiara Cassani, Lorena Incorvaia, et al.. (2023). 42P Efficacy of maintenance with PARPi in advanced ovarian cancer according to the location of BRCA mutation. ESMO Open. 8(1). 100822–100822.
7.
Giudice, Elena, et al.. (2023). Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives. Current Oncology Reports. 25(11). 1307–1326.
8.
Musacchio, Lucia, Serena Maria Boccia, Cláudia Marchetti, et al.. (2023). Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors. International Journal of Gynecological Cancer. 33(6). 922–928.
9.
Salutari, Vanda, Cláudia Marchetti, Viola Ghizzoni, et al.. (2023). #881 The NUVOLA TRIAL: neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel. A phase II open-label multi-centre study. A430.3–A431.
10.
Agostinelli, Veronica, Lucia Musacchio, Floriana Camarda, et al.. (2023). Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data. Cancer Management and Research. Volume 15. 1063–1072.
11.
Salutari, Vanda, Viola Ghizzoni, Elena Giudice, et al.. (2023). Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience. International Journal of Gynecological Cancer. 33(4). 514–520.
12.
Musacchio, Lucia, Vanda Salutari, Sandro Pignata, et al.. (2022). 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer. International Journal of Gynecological Cancer. 32. A347–A348.
13.
Salutari, Vanda, Lucia Musacchio, Sandro Pignata, et al.. (2022). 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician’s choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). International Journal of Gynecological Cancer. 32. A356–A356.
14.
Ghirardi, Valentina, et al.. (2022). Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Management of Advanced Ovarian Cancer. A Literature Review. European Journal of Gynaecological Oncology. 43(2). 335–335.
15.
Nero, Camilla, Elena Giudice, Vanda Salutari, et al.. (2022). Advanced and recurrent endometrial cancer: State of the art and future perspectives. Critical Reviews in Oncology/Hematology. 180. 103851–103851.
16.
Nero, Camilla, et al.. (2022). Management of stage III and IVa uterine cancer. International Journal of Gynecological Cancer. 32(3). 316–322.
17.
Giudice, Elena, Vanda Salutari, Caterina Ricci, et al.. (2021). Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review. Critical Reviews in Oncology/Hematology. 168. 103542–103542.
18.
Musacchio, Lucia, Vanda Salutari, Sandro Pignata, et al.. (2021). Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). International Journal of Gynecological Cancer. 31(10). 1369–1373.
19.
Giudice, Elena, Floriana Camarda, Vanda Salutari, et al.. (2021). Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives. 17(2). 68–68.
20.
Lorusso, Domenica, Cláudia Marchetti, Carmine Conte, et al.. (2020). Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study. Gynecologic Oncology. 159(1). 95–100.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Lorena Fariñas-Madrid Breakdown of academic impact, for papers by Daliah Tsoref Breakdown of academic impact, for papers by Beata Maćkowiak-Matejczyk Breakdown of academic impact, for papers by Irina Tsibulak Breakdown of academic impact, for papers by Justin Harold Breakdown of academic impact, for papers by Imre Pete Breakdown of academic impact, for papers by Koji Nishino Breakdown of academic impact, for papers by Tong Shu Breakdown of academic impact, for papers by И. В. Берлев Breakdown of academic impact, for papers by A.M. Newtson